33090679|t|Self-reported obstructive sleep apnea, amyloid and tau burden, and Alzheimer's disease time-dependent progression.
33090679|a|INTRODUCTION: Obstructive sleep apnea (OSA) is associated with Alzheimer's disease (AD) biomarkers in cognitively normal (CN) and mild cognitive impaired (MCI) participants. However, independent and combined effects of OSA, amyloid beta (Abeta) and tau-accumulation on AD time-dependent progression risk is unclear. METHODS: Study participants grouped by biomarker profile, as described by the A/T/N scheme, where "A" refers to aggregated Abeta, "T" aggregated tau, and "N" to neurodegeneration, included 258 CN (OSA-positive [OSA+] [A+TN+ n = 10, A+/TN- n = 6, A-/TN+ n = 10, A-/TN- n = 6 and OSA-negative [OSA-] [A+TN+ n = 84, A+/TN- n = 11, A-/TN+ n = 96, A-/TN- n = 36]) and 785 MCI (OSA+ [A+TN+ n = 35, A+/TN- n = 15, A-/TN+ n = 25, A-/TN- n = 16] and OSA- [A+TN+ n = 388, A+/TN- n = 28, A-/TN+ n = 164, A-/TN- n = 114]) older-adults from the Alzheimer's Disease Neuroimaging Initiative cohort. Cox proportional hazards regression models estimated the relative hazard of progression from CN-to-MCI and MCI-to-AD, among baseline OSA CN and MCI patients, respectively. Multi-level logistic mixed-effects models with random intercept and slope investigated the synergistic associations of self-reported OSA, Abeta, and tau burden with prospective cognitive decline. RESULTS: Independent of TN-status (CN and MCI), OSA+/Abeta+ participants were approximately two to four times more likely to progress to MCI/AD (P < .001) and progressed 6 to 18 months earlier (P < .001), compared to other participants combined (ie, OSA+/Abeta-, OSA-/Abeta+, and OSA-/Abeta-). Notably, OSA+/Abeta- versus OSA-/Abeta- (CN and MCI) and OSA+/TN- versus OSA-/TN- (CN) participants showed no difference in the risk and time-to-MCI/AD progression. Mixed effects models demonstrated OSA synergism with Abeta (CN and MCI [beta = 1.13, 95% confidence interval (CI), 0.74 to 1.52, and beta = 1.18, 95%CI, 0.82 to 1.54]) respectively, and with tau (MCI [beta = 1.31, 95% CI, 0.87 to 1.47]), P < .001 for all. DISCUSSION: OSA acts in synergism with Abeta and with tau, and all three acting together result in synergistic neurodegenerative mechanisms especially as Abeta and tau accumulation becomes increasingly abnormal, thus leading to shorter progression time to MCI/AD in CN and MCI-OSA patients, respectively.
33090679	14	37	obstructive sleep apnea	Disease	MESH:D020181
33090679	51	54	tau	Gene	4137
33090679	67	86	Alzheimer's disease	Disease	MESH:D000544
33090679	129	152	Obstructive sleep apnea	Disease	MESH:D020181
33090679	154	157	OSA	Disease	MESH:D020181
33090679	178	197	Alzheimer's disease	Disease	MESH:D000544
33090679	199	201	AD	Disease	MESH:D000544
33090679	250	268	cognitive impaired	Disease	MESH:D003072
33090679	270	273	MCI	Disease	MESH:D060825
33090679	334	337	OSA	Disease	MESH:D020181
33090679	339	351	amyloid beta	Gene	351
33090679	353	358	Abeta	Gene	351
33090679	364	367	tau	Gene	4137
33090679	384	386	AD	Disease	MESH:D000544
33090679	554	559	Abeta	Gene	351
33090679	576	579	tau	Gene	4137
33090679	592	609	neurodegeneration	Disease	MESH:D019636
33090679	628	631	OSA	Disease	MESH:D020181
33090679	642	645	OSA	Disease	MESH:D020181
33090679	709	712	OSA	Disease	MESH:D020181
33090679	723	726	OSA	Disease	MESH:D020181
33090679	798	801	MCI	Disease	MESH:D060825
33090679	803	806	OSA	Disease	MESH:D020181
33090679	872	875	OSA	Disease	MESH:D020181
33090679	963	982	Alzheimer's Disease	Disease	MESH:D000544
33090679	1114	1117	MCI	Disease	MESH:D060825
33090679	1122	1125	MCI	Disease	MESH:D060825
33090679	1129	1131	AD	Disease	MESH:D000544
33090679	1148	1151	OSA	Disease	MESH:D020181
33090679	1159	1162	MCI	Disease	MESH:D060825
33090679	1163	1171	patients	Species	9606
33090679	1320	1323	OSA	Disease	MESH:D020181
33090679	1325	1330	Abeta	Gene	351
33090679	1336	1339	tau	Gene	4137
33090679	1364	1381	cognitive decline	Disease	MESH:D003072
33090679	1425	1428	MCI	Disease	MESH:D060825
33090679	1431	1434	OSA	Disease	MESH:D020181
33090679	1436	1441	Abeta	Gene	351
33090679	1520	1523	MCI	Disease	MESH:D060825
33090679	1524	1526	AD	Disease	MESH:D000544
33090679	1633	1636	OSA	Disease	MESH:D020181
33090679	1638	1643	Abeta	Gene	351
33090679	1646	1649	OSA	Disease	MESH:D020181
33090679	1651	1656	Abeta	Gene	351
33090679	1663	1666	OSA	Disease	MESH:D020181
33090679	1668	1673	Abeta	Gene	351
33090679	1686	1689	OSA	Disease	MESH:D020181
33090679	1691	1696	Abeta	Gene	351
33090679	1705	1708	OSA	Disease	MESH:D020181
33090679	1710	1715	Abeta	Gene	351
33090679	1725	1728	MCI	Disease	MESH:D060825
33090679	1734	1737	OSA	Disease	MESH:D020181
33090679	1750	1753	OSA	Disease	MESH:D020181
33090679	1822	1825	MCI	Disease	MESH:D060825
33090679	1826	1828	AD	Disease	MESH:D000544
33090679	1876	1879	OSA	Disease	MESH:D020181
33090679	1895	1900	Abeta	Gene	351
33090679	1909	1912	MCI	Disease	MESH:D060825
33090679	2033	2036	tau	Gene	4137
33090679	2038	2041	MCI	Disease	MESH:D060825
33090679	2110	2113	OSA	Disease	MESH:D020181
33090679	2137	2142	Abeta	Gene	351
33090679	2152	2155	tau	Gene	4137
33090679	2252	2257	Abeta	Gene	351
33090679	2262	2265	tau	Gene	4137
33090679	2354	2357	MCI	Disease	MESH:D060825
33090679	2358	2360	AD	Disease	MESH:D000544
33090679	2371	2374	MCI	Disease	MESH:D060825
33090679	2375	2378	OSA	Disease	MESH:D020181
33090679	2379	2387	patients	Species	9606
33090679	Association	MESH:D019636	4137
33090679	Association	MESH:D000544	4137
33090679	Association	MESH:D003072	351
33090679	Association	MESH:D000544	351
33090679	Association	MESH:D003072	4137

